关键词: 肺肿瘤, 乙型肝炎病毒, 肝功能不全, 抗病毒治疗

Abstract: Background　Due to the high prevalence of primary bronchogenic carcinoma （lung cancer） and hepatitis B virus infection in China，lung cancer patients infected with HBV are common.Some studies found that lung cancer patients who infected with HBV have higher rates of liver damage and hepatitis B virus reactivation（HBVR）than those without HBV.Objective　To investigate the effect of prophylactic antiviral therapy on hepatic impairment and hepatitis B virus reactivation（HBVR） in lung cancer patients with hepatitis B virus surface antigen（HBsAg） infection.Methods　According to the inclusion and exclusion criteria，from Changhai Hospital during 2015 to 2017，we enrolled 61 lung cancer inpatients with positive HBsAg test result（HBsAg-positive group），including 29 who received prophylactic antiviral therapy（intervention subgroup） and 32 who did not（control subgroup），and other 61 lung caner inpatients without HBsAg infection（HBsAg-negative group）．The incidence of hepatic impairment was compared between the intervention subgroup，control subgroup and HBsAg-negative group.And the incidence of HBVR was compared between the intervention subgroup and the control subgroup.Results　The incidence of hepatic impairment in the control subgroup was higher than that in the HBsAg-negative group at the first third hospitalization（P<0.05）．At the first hospitalization，the incidence of hepatic impairment in the HBsAg-negative group was lower than that in the intervention subgroup（P<0.05）．At the first third and fifth hospitalizations，there was no significant difference in the incidence of hepatic impairment between the intervention subgroup and  the control subgroup（P>0.05）．There was no significant difference in the incidence of HBVR between the intervention subgroup and the control subgroup（P>0.05）．Conclusion　HBV infection can significantly increase the risk of hepatic impairment in lung cancer patients during antitumor therapy.But the absolute risk of hepatic impairment in this population during antitumor therapy can be reduced by prophylactic antiviral therapy．

Key words: Lung neoplasms, Hepatitis B virus, Hepatic insufficiency, Antivirus therapy